The U.S. Food and Drug Administration has approved gene therapy for treating children with Spinal Mu


          The US FDA has approved Novartis to supply a gene therapy called Zolgensma, for treating spinal muscular atrophy (SMA). This treatment costs about $ 2.1 million. The treatment can completely cure SMA, but at the highest ever cost for gene therapy.


Page view : 559